Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, Gajdos GB, Chandok N, Bakeberg JL, Ward CJ, Ritman EL, Kiyokawa H, LaRusso NF.

Gastroenterology. 2012 Mar;142(3):622-633.e4. doi: 10.1053/j.gastro.2011.11.036.

2.

VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.

Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB.

Am J Physiol Cell Physiol. 2007 Jul;293(1):C419-28.

3.

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF.

Gastroenterology. 2007 Mar;132(3):1104-16.

PMID:
17383431
4.

MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.

Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, Larusso N.

J Clin Invest. 2008 Nov;118(11):3714-24. doi: 10.1172/JCI34922.

5.

Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice.

Doctor RB, Serkova NJ, Hasebroock KM, Zafar I, Edelstein CL.

Nephrol Dial Transplant. 2010 Nov;25(11):3496-504. doi: 10.1093/ndt/gfq195.

6.

Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF.

Hepatology. 2013 Jul;58(1):409-21. doi: 10.1002/hep.26140.

7.

Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

Yoshihara D, Kugita M, Sasaki M, Horie S, Nakanishi K, Abe T, Aukema HM, Yamaguchi T, Nagao S.

PLoS One. 2013 Dec 6;8(12):e81480. doi: 10.1371/journal.pone.0081480.

8.

Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.

Masyuk TV, Lee SO, Radtke BN, Stroope AJ, Huang B, Banales JM, Masyuk AI, Splinter PL, Gradilone SA, Gajdos GB, LaRusso NF.

Am J Pathol. 2014 Jan;184(1):110-21. doi: 10.1016/j.ajpath.2013.09.021.

9.

The zebrafish as a model to study polycystic liver disease.

Tietz Bogert PS, Huang BQ, Gradilone SA, Masyuk TV, Moulder GL, Ekker SC, Larusso NF.

Zebrafish. 2013 Jun;10(2):211-7. doi: 10.1089/zeb.2012.0825.

10.

Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.

Wang X, Ye H, Ward CJ, Chu JY, Masyuk TV, Larusso NF, Harris PC, Chow BK, Torres VE.

Am J Physiol Renal Physiol. 2012 Oct;303(7):F1089-98. doi: 10.1152/ajprenal.00242.2012.

11.

Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.

Wang X, Harris PC, Somlo S, Batlle D, Torres VE.

Nephrol Dial Transplant. 2009 Feb;24(2):526-34. doi: 10.1093/ndt/gfn527.

12.

Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Sáez E, Úriz M, Sarvide S, Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso Á, Hijona E, Jimenez-Agüero R, Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM.

J Hepatol. 2015 Oct;63(4):952-61. doi: 10.1016/j.jhep.2015.05.023.

13.

Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney disease.

Stroope A, Radtke B, Huang B, Masyuk T, Torres V, Ritman E, LaRusso N.

Am J Pathol. 2010 Mar;176(3):1282-91. doi: 10.2353/ajpath.2010.090658.

14.

A role for microRNA in cystic liver and kidney diseases.

Chu AS, Friedman JR.

J Clin Invest. 2008 Nov;118(11):3585-7. doi: 10.1172/JCI36870.

15.

HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.

Gradilone SA, Habringer S, Masyuk TV, Howard BN, Masyuk AI, Larusso NF.

Am J Pathol. 2014 Mar;184(3):600-8. doi: 10.1016/j.ajpath.2013.11.027.

16.

The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).

Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF.

Hepatology. 2009 Jan;49(1):160-74. doi: 10.1002/hep.22636.

17.

Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease.

Muff MA, Masyuk TV, Stroope AJ, Huang BQ, Splinter PL, Lee SO, Larusso NF.

Lab Invest. 2006 Sep;86(9):940-50.

18.

Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Urribarri AD, Munoz-Garrido P, Perugorria MJ, Erice O, Merino-Azpitarte M, Arbelaiz A, Lozano E, Hijona E, Jiménez-Agüero R, Fernandez-Barrena MG, Jimeno JP, Marzioni M, Marin JJ, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Banales JM.

Gut. 2014 Oct;63(10):1658-67. doi: 10.1136/gutjnl-2013-305281.

19.

Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.

Gradilone SA, Masyuk TV, Huang BQ, Banales JM, Lehmann GL, Radtke BN, Stroope A, Masyuk AI, Splinter PL, LaRusso NF.

Gastroenterology. 2010 Jul;139(1):304-14.e2. doi: 10.1053/j.gastro.2010.04.010.

20.

Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.

Banales JM, Masyuk TV, Bogert PS, Huang BQ, Gradilone SA, Lee SO, Stroope AJ, Masyuk AI, Medina JF, LaRusso NF.

Am J Pathol. 2008 Dec;173(6):1637-46. doi: 10.2353/ajpath.2008.080125.

Supplemental Content

Support Center